Pharmaceuticals & Therapeutics

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

A new FDA-cleared shoulder implant from FX Shoulder Solutions offers unprecedented flexibility, allowing surgeons to adapt their approach mid-surgery.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

LANGLARA, a new Lantus biosimilar, gains FDA approval, promising more affordable diabetes care. But it faces a tough fight in a competitive market.

A new testing platform from Armatus Bio aims to break a major bottleneck in gene therapy, promising faster paths to cures for rare neuromuscular diseases.

A devastating infant liver disorder meets a potential breakthrough. Satellite Bio's novel cell therapy just received a critical FDA nod, paving the way for trials.

The biopharma firm gets a significant non-dilutive cash infusion, bolstering its finances to advance a promising oncology pipeline without equity dilution.

Spanish CDMO ROIS acquires a major Phoenix facility from Bristol Myers Squibb, securing US drug supply chains and expanding its global footprint.

Amidst a culture of delayed self-care, CARiNG Pharmacy launches a major campaign to shift women's health from reactive treatment to proactive wellness.

A new company emerges from Purdue Pharma's bankruptcy, owned by a non-profit and tasked with fighting the very opioid crisis its predecessor fueled.

Consumers and insurers who bought QVAR inhalers may get cash from a $35M settlement over claims Teva illegally blocked cheaper generic alternatives.

The K-beauty brand expands into Mexico's booming market, but safety claims face scrutiny as reports of adverse effects surface in other regions.

Navigating life after a stroke can be isolating. A Maywood event offers a comprehensive network of support, resources, and inspiration for the journey.

Following a year of record profits, Cipher Pharmaceuticals is renewing its share buyback program, signaling a strong belief that its stock is undervalued.

Medcura adds a Johnson & Johnson heavyweight to its board, aiming to disrupt the surgical hemostasis market with its FDA-designated breakthrough gel, LifeGel.

A $1M grant funds research into an ultra-rare cancer's defense mechanism, offering new hope against a disease with a grim 10% survival rate.